The American Society of Clinical Oncology (ASCO) annual meeting is a flagship event in the global oncology calendar aimed at providing healthcare professionals, patient advocates, industry representatives, and major media outlets worldwide with the latest developments in cancer treatments.
As part of our social media listening offering, APLUSA has been analyzing online conversations around the ASCO events since 2019. You can check out our findings from last year’s edition.
>>>>>>>>>> Read SOCIAL MEDIA INSIGHTS: ASCO 2021 blog post <<<<<<<<<<
More discussions compared to 2020 and 2021
Consistent with the trend already seen last year, the volume of mentions went up 14% going from 77K in 2021 to 87k mentions in 2022. This represents an increase of 14%.
This shows that the volume of mentions is almost recovering pre-pandemic level when there were 91K mentions in 2019. It is important to note the large dip that occurred in 2020, the year of the pandemic, with 65K mentions.
Greater engagement from all participants
Last year, the biggest increase in mentions came from HCPs. This year, however, pharma companies saw the biggest increase in participation going from 665 mentions in 2021 to 1458 in 2022, surging 119%.
Organizations’ participation also saw significant growth, going up from 8020 in 2021 to 10 604 in 2022, a rise of 32%.
HCPs’ participation saw a modest increase in participation going up 3% from 30 002 mentions in 2021 to 31 024 in 2022. It is interesting to note that this follows last year’s significant surge when participation HCPs jumped 70%, indicating that pharma companies and organizations are only catching up this year.
Lung and breast cancers are the most discussed
Lung and breast cancers remain the most discussed cancer types. This is fueled by encouraging results from multiple clinical trials in lung cancer. In Breast cancer, the most discussed trial was DESTINY-Breast04.
Changing practice results from the DESTINY-Breast4 clinical trial
The posts from HCPs generating the most engagement were about Multiple Myeloma and Breast cancer.
HCPs hailed the results from the DESTINY-Breast04 clinical trial as providing significant advancement for HER2-low patients. This includes improvement of median progression-free survival and median overall survival. Healthcare professionals online expressed enthusiasm towards this news. Headlines dubbed Trastuzumab Deruxtecanas as a new standard of care and practice changing.
Influencer Dr. Vincent Rajkumar shed light on Multiple Myeloma treatments. The Twitter thread summarizes the treatments used in Multiple Myeloma. The thread, mostly educational, was created in anticipation of the results presented during the different ASCO events as a reference to what might come during the event itself.
We will run another social media impact analysis on the forthcoming ASH conference happening in December, where APLUSA will also be an exhibitor.
